Lung cancer kills more people annually than any other malignancy, and the persistence of drug resistance alongside tumour heterogeneity means that even the most sophisticated targeted therapies eventually lose their edge. A comprehensive new framework for understanding where radiopharmaceutical precision medicine stands — and where it is heading — arrives at a pivotal moment, as the field transitions from broad cytotoxic approaches toward tumour-specific irradiation at the molecular level.
This systematic landscape review, drawing on PubMed and ClinicalTrials.gov records through January 2026, catalogued 66 distinct radionuclide-drug conjugates (RDCs) evaluated in lung cancer contexts, of which 30 have advanced into early-phase clinical trials. The evolutionary arc is striking: early clinical work relied on iodine-131 and yttrium-90 conjugated to antibodies, but the field has converged markedly on lutetium-177 paired with somatostatin receptor (SSTR)-targeting peptides. A meaningful tactical refinement has also emerged within SSTR-directed therapy — a shift from receptor agonists toward antagonists, which appear to achieve superior tumour uptake without triggering receptor internalization in ways that limit imaging fidelity. Beyond SSTR, three rising targets — fibroblast activation protein (FAP), epidermal growth factor receptor (EGFR), and programmed death-ligand 1 (PD-L1) — are attracting intensifying preclinical and early clinical interest. Structurally, the delivery vehicle landscape is diversifying: bispecific antibodies, single-domain antibodies, cyclic peptides, and nanoparticle platforms are all advancing, each offering distinct pharmacokinetic and tumour-penetration profiles.
The significance here extends beyond lung cancer specifically. Lutetium-177 DOTATATE's established approval in neuroendocrine tumours has validated the RDC framework clinically, and lung cancer represents the next high-stakes proving ground given its prevalence and resistance burden. The agonist-to-antagonist pivot in SSTR targeting mirrors lessons already absorbed in the neuroendocrine field, suggesting productive cross-tumour learning. That said, this is a review of preclinical and early-phase data — phase III confirmatory evidence for most of these 30 clinical candidates remains absent. Tumour heterogeneity in lung cancer, particularly between small-cell and non-small-cell subtypes, creates real selection challenges for any single-target approach. The nanoparticle and bispecific antibody entrants are especially early-stage. Still, the density of candidates and the mechanistic sophistication now evident make this landscape more than incremental — it represents a genuine platform shift in oncologic radiopharmaceuticals.